Abstract:Adoptive transfer of engineered T cells has shown dramatic responses in blood cancers, but efficacy in more common solid tumors has been limited in part by poor persistence and T cell dysfunction. Studies of endogenous T cells in solid tumors have established that tumor-draining lymph nodes (TdLNs) harbor a population of stem-like PD-1+Tcf1+ progenitor exhausted T cells (Tpex) that can self-renew and continuously replenish functional T cells in tumors. Tpex in TdLNs are also the population that responds to PD-1/PD-L1 checkpoint blockade, highlighting the importance of TdLNs for T cell responses to solid tumors. It is not clear, however, whether engineered T cells form a similar stem-like Tpex population in TdLNs that can sustain effector T cell responses in the tumor or be enhanced by PD-L1 blockade. To test this, we adapted the Kras/p53 mouse model of lung cancer to express the TCR neoantigen ovalbumin (KPOva), enabling comparison of engineered T cells (TCR-T) and endogenous T cells (Endog-T) targeting the same tumor antigen. We activated Ova-specific OT-Is with anti-CD3/CD28 and expanded them in vitro with IL-2 and IL-15 to generate Ova-specific TCR-T cells, and we used SIINFEKL/H2-Kb tetramer to identify Ova-specific Endog-T cells. KPOva mice were left untreated or treated with cyclophosphamide (Cy) for lymphodepletion and infused with 1x106 OT-I TCR-T cells, mimicking clinical protocols. As expected, Endog-Ts preferentially accumulated in TdLNs and adopted a PD-1+Tcf1+ Tpex phenotype. TCR-Ts also preferentially accumulated in TdLNs; however, TCR-Ts showed reduced PD-1 upregulation compared to Endog-Ts, with many adopting a PD-1-Tcf1+ central memory phenotype, reflecting lack of activation. Interestingly, whereas Endog-Ts interacted with DCs in TdLNs at a ∼1:1 ratio, TCR-Ts swarmed DCs, forming clusters of 10-30+ cells. Cy treatment also depleted 70% of DCs in TdLNs, further skewing the TCR-T:DC ratio in the TdLN. We hypothesize that TCR-T compete for limited antigen presentation by DCs in TdLNs, impairing their upregulation of PD-1. Consistent with this hypothesis, infusion of 100-fold fewer TCR-Ts resulted in equivalent PD-1 upregulation in TdLNs as observed on Endog-Ts, indicating that reducing competition can restore TCR-T activation in TdLNs. Lastly, PD-L1 blockade boosted Endog-Ts in TdLNs and significantly improved tumor control, but PD-L1 blockade drove terminal differentiation of TCR-Ts in TdLNs and did not enhance TCR-T-mediated tumor control, showing that reduced PD-1 upregulation in TdLNs may limit TCR-T synergy with PD-L1 blockade. This study highlights that Cy followed by infusion of clinically relevant doses of TCR-Ts induces competition for DCs in TdLNs, potentially limiting TCR-T activation here and synergy with PD-1/PD-L1 blockade. Our work suggests that strategies to reduce competition, by selectively limiting TCR-T accumulation in TdLNs and/or boosting antigen-presentation by DCs in TdLNs, may sensitize TCR-T therapy to PD-L1 blockade and enable more effective control of solid tumors. Citation Format: Sam Nutt, Jessica Huang, Emma Bingham, Michael Gerner, Shivani Srivastava. Competition for dendritic cells limits engineered TCR-T cell activation in tumor-draining lymph nodes and impairs synergy with PD-L1 blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-03.

PGE 2 limits effector expansion of tumour-infiltrating stem-like CD8 + T cells

PGE 2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function

Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

Abstract 4985: Pivotal roles for cancer cell-intrinsic mPGES-1 and autocrine EP4 signaling in suppressing anti-tumor immunity

Abstract A019: Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells infiltrating human tumor

EP2/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s

Abstract B033: Tumor cell-intrinsic mPGES-1-PGE2-EP4 signaling is a major immunosuppressive pathway in pancreatic cancer

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment

Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells

Synergistic COX2 induction by IFNγ and TNFα self-limits type-1 immunity in cancer tissues (TUM10P.1027)

Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity

Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses

Abstract PR-03: Competition for dendritic cells limits engineered TCR-T cell activation in tumor-draining lymph nodes and impairs synergy with PD-L1 blockade

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy